Showing results (311-320 of 432) with videos related to
Sort By:
Pageof 44
Plos One|November 8, 2012
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variantsFrancesc Vidal, Miguel López-Dupla, Montserrat Laguno, et al.Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|January 13, 2024
The impact of the COVID-19 pandemic on healthcare services utilization among people living with HIV in Catalonia, Spain: A population-based cohort studyYi-Hua Pan, Daniel K Nomah, Marcos Montoro-Fernandez, et al.Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.Clinical Immunology (Orlando, Fla.)|November 15, 2020
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohortHèctor Corominas, Ivan Castellví, Virginia Pomar, et al.HIV Clinical Trials|October 23, 2013
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP studyJosé Ramón Blanco, Ana María Caro-Murillo, Manuel Angel Castaño, et al.The Journal of Infectious Diseases|April 1, 2024
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIVJuan Berenguer, Inmaculada Jarrín, José M Bellón, et al.The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.Journal of Medical Virology|July 21, 2005
Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patientsBerta Rodes, Federico García, Carolina Gutierrez, et al.AIDS (London, England)|November 8, 2017
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular riskJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.BMC Public Health|August 29, 2021
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping reviewJorge Palacio-Vieira, Juliana Maria Reyes-Urueña, Arkaitz Imaz, et al.Pageof 44